<DOC>
	<DOCNO>NCT00710268</DOCNO>
	<brief_summary>Phase I , open label , dual centre , dose find study evaluate safety tolerability continuous twice daily oral dose AZD2281 administer combination Bevacizumab 10mg/kg give every 2 week patient advance solid tumour .</brief_summary>
	<brief_title>Study Assess Safety &amp; Tolerability AZD2281 Combination With Bevacizumab Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Histologically confirm metastatic cancer , amenable surgery radiation therapy curative intent Adequate bone marrow , kidney liver function accordance laboratory parameter set protocol Estimated life expectancy least 12 week Disorders may put patient risk bleeding , include gastrointestinal perforation , intraabdominal abcess , major surgery chest abdomen , previous haemorrhage , cough blood thrombotic event Hypertension ( high blood pressure ) significant cardiovascular disease Hypersensitivity Chinese hamster ovary cell product recombinant humanised antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>Poly ( ADP ribose ) polymerase</keyword>
	<keyword>Metastatic Solid Tumours</keyword>
	<keyword>PARP inhibitor</keyword>
</DOC>